Handelsbanken Fonder
MLTX icon

Handelsbanken Fonder’s MoonLake Immunotherapeutics MLTX Stock Holding History

Handelsbanken Fonder’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,600
Closed -$76K – 1530
2025
Q3 		$76K Hold
10,600
– – ﹤0.01% 1498
2025
Q2 		$500K Sell
10,600
-500
-5% -$20.4K ﹤0.01% 1250
2025
Q1 		$434K Hold
11,100
– – ﹤0.01% 1294
2024
Q4 		$601K Sell
11,100
-1,900
-15% -$97K ﹤0.01% 1220
2024
Q3 		$655K Buy
13,000
+2,700
+26% +$127K ﹤0.01% 1123
2024
Q2 		$453K Buy
+10,300
New +$436K ﹤0.01% 1202

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Handelsbanken Fonder's MLTX Position: Q4 2025 in Review

Handelsbanken Fonder sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 10,600 shares — an estimated $76K sold.

Handelsbanken Fonder first reported a position in MLTX in Q2 2024 and held it in 6 quarters. The position peaked at $655K in Q3 2024. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

  • Handelsbanken Fonder reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Handelsbanken Fonder sold 10,600 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $76K.
  • Handelsbanken Fonder first reported a position in MoonLake Immunotherapeutics in Q2 2024 and held it in 6 quarters.
  • Handelsbanken Fonder's MoonLake Immunotherapeutics position peaked at $655K in Q3 2024.
  • 130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Handelsbanken Fonder's 13F filing for Q4 2025, filed 6 Feb 2026.